CLAIMS

What is claimed is:

1. A compound of the general formula (I):



(I)

wherein X_1 is aryl or heteroaryl each of which is optionally substituted with one or more substituents selected from

- halogen, hydroxy, cyano, amino or carboxy; or
- C_{1-6}-alkyl, C_{3-6}-cycloalkyl, C_{2-6}-alkenyl, C_{2-6}-alkynyl, aryl, aralkyl, heteroaryl, heteroaralkyl, C_{1-6}-alkoxy, C_{3-6}-cycloalkoxy, aryloxy, aralkoxy, heteroaralkoxy, C_{1-6}-alkylthio, arylthio, C_{3-6}-cycloalkylthio, C_{1-6}-alkylcarbonyl, arylcarbonyl, C_{1-6}-alkylsulfonyl, arylsulfonyl, C_{1-6}-alkylsulfonyloxy, arylsulfonyloxy, C_{1-6}-alkylamido, arylamido, C_{1-6}-alkylaminocarbonyl, C_{1-6}-alkylamino, C_{1-6}-dialkylamino or C_{3-6}-cycloalkylamino each of which is optionally substituted with one or more halogens; and

X_2 is arylene or heteroarylene each of which is optionally substituted with one or more substituents selected from

- halogen, hydroxy, cyano, amino or carboxy; or
- C_{1-6}-alkyl, C_{3-6}-cycloalkyl, C_{2-6}-alkenyl, C_{2-6}-alkynyl, C_{1-6}-alkoxy, C_{3-6}-cycloalkoxy, C_{1-6}-alkylthio, C_{3-6}-cycloalkylthio, C_{1-6}-alkylamino, C_{1-6}-dialkylamino or C_{3-6}-cycloalkylamino each of which is optionally substituted with one or more halogens; and

X_3 is aryl or heteroaryl each of which is optionally substituted with one or more substituents selected from

- halogen, hydroxy, cyano, amino or carboxy; or
- C_{1-6}-alkyl, C_{3-6}-cycloalkyl, C_{2-6}-alkenyl, C_{2-6}-alkynyl, aralkyl, heteroaralkyl, C_{1-6}-alkoxy, C_{3-6}-cycloalkoxy, aryloxy, aralkoxy, heteroaralkoxy, C_{1-6}-alkylthio, arylthio, C_{3-6}-cycloalkylthio, C_{1-6}-alkylcarbonyl, arylcarbonyl, C_{1-6}-alkylsulfonyl, arylsulfonyl, C_{1-6}-alkylsulfonyloxy, arylsulfonyloxy, C_{1-6}-alkylamido, arylamido, C_{1-6}-alkylaminocarbonyl, C_{1-6}-

alkylamino, C_{1-6}-dialkylamino or C_{3-6}-cycloalkylamino each of which is optionally substituted with one or more halogens; and

Ar is arylene which is optionally substituted with one or more substituents selected from

- halogen, hydroxy or cyano; or
- C_{1-6}-alkyl, C_{3-6}-cycloalkyl, C_{2-6}-alkenyl, C_{2-6}-alkynyl, aryl, heteroaryl, aralkyl, heteroaralkyl, C_{1-6}-alkoxy, C_{3-6}-cycloalkoxy, aryloxy, aralkoxy, heteroaralkoxy, C_{1-6}-alkylthio, arylthio or C_{3-6}-cycloalkylthio each of which is optionally substituted with one or more halogens; and

Y_1 is O or S; and

Y_2 is O or S; and

Z is $-(CH_2)_n-$ wherein n is 1, 2 or 3; and

R_1 is hydrogen, halogen or a substituent selected from

- C_{1-6}-alkyl, C_{3-6}-cycloalkyl, C_{2-6}-alkenyl, C_{2-6}-alkynyl, aralkyl, heteroaralkyl, C_{1-6}-alkoxy, C_{3-6}-cycloalkoxy, aryloxy, aralkoxy, heteroaralkoxy, C_{1-6}-alkylthio, arylthio or C_{3-6}-cycloalkylthio each of which is optionally substituted with one or more halogens; and

R_2 is hydrogen, C_{1-6}-alkyl, C_{3-6}-cycloalkyl, C_{2-6}-alkenyl, C_{2-6}-alkynyl, C_{4-6}-alkenynyl or aryl; or

a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, tautomeric form, stereoisomer, mixture of stereoisomers, racemic mixture, or polymorphs thereof.

2. A compound according to claim 1, wherein X_1 is aryl or heteroaryl optionally substituted with one or more substituents selected from

- halogen; or
- C_{1-6}-alkyl, aryl, C_{1-6}-alkoxy, C_{1-6}-alkylsulfonyl or C_{1-6}-alkylsulfonyloxy each of which is optionally substituted with one or more halogens.

3. A compound according to claim 2, wherein X_1 is phenyl, furyl, thienyl, benzothienyl or benzofuranyl optionally substituted with one or more substituents selected from

- halogen; or

- C_{1-6}-alkyl, aryl, C_{1-6}-alkoxy, C_{1-6}-alkylsulfonyl or C_{1-6}-alkylsulfonyloxy each of which is optionally substituted with one or more halogens.

4. A compound according to claim 3, wherein X_1 is phenyl optionally substituted with one or more substituents selected from halogen, C_{1-6}-alkyl, aryl or perhalomethyl.

5. A compound according to claim 4, wherein X_1 is phenyl optionally substituted with one or more substituents seleced from phenyl or trifluoromethyl.

6. A compound according to claim 5, wherein X_1 is phenyl.

7. A compound according to claim 3, wherein X_1 is furyl, thienyl, benzothienyl or benzofuranyl with one or more substituents seleced from halogen, C_{1-6}-alkyl, aryl or perhalomethyl.

8. A compound according to claim 7, wherein X_1 is furyl optionally substituted with one or more substituents seleced from halogen, C_{1-6}-alkyl, phenyl or trifluoromethyl.

9. A compound according to claim 7, wherein X_1 is thienyl optionally substituted with one or more substituents seleced from halogen, C_{1-6}-alkyl, phenyl or trifluoromethyl.

10. A compound according to claim 7, wherein X_1 is benzothienyl optionally substituted with one or more substituents seleced from halogen, C_{1-6}-alkyl, phenyl or trifluoromethyl.

11. A compound according to claim 1, wherein X_2 is arylene or heteroarylene optionally substituted with one or more substituents selected from

- halogen; or
- C_{1-6}-alkyl or C_{1-6}-alkoxy each of which is optionally substituted with one or more halogens.

12. A compound according to claim 11, wherein X_2 is phenylene optionally substituted with one or more substituents selected from

- halogen; or
- C_{1-6}-alkyl or C_{1-6}-alkoxy each of which is optionally substituted with one or more halogens.

13. A compound according to claim 12, wherein X_2 is phenylene optionally substituted with one or more halogens.

14. A compound according to claim 13, wherein X_2 is phenylene.

15. A compound according to claim 11, wherein X_2 is benzofuranylene optionally substituted with one or more substituents selected from

- halogen; or
- C_{1-6}-alkyl or C_{1-6}-alkoxy each of which is optionally substituted with one or more halogens.

16. A compound according to claim 15, wherein X_2 is benzofuranylene optionally substituted with C_{1-6}-alkyl.

17. A compound according to claim 1, wherein X_3 is aryl or heteroaryl optionally substituted with one or more substituents selected from

- halogen; or
- C_{1-6}-alkyl, C_{1-6}-alkoxy, C_{1-6}-alkylsulfonyl or C_{1-6}-alkylsulfonyloxy each of which is optionally substituted with one or more halogens.

18. A compound according to claim 17, wherein X_3 is phenyl, furyl, thienyl, benzothienyl or benzofuranyl optionally substituted with one or more substituents selected from

- halogen; or
- C_{1-6}-alkyl, C_{1-6}-alkoxy, C_{1-6}-alkylsulfonyl or C_{1-6}-alkylsulfonyloxy each of which is optionally substituted with one or more halogens.

19. A compound according to claim 18, wherein X_3 is phenyl optionally substituted with one or more halogens.

20. A compound according to claim 18, wherein X_3 is phenyl optionally substituted with one or more substituents selected from C_{1-6}-alkyl or perhalomethyl.

21. A compound according to claim 18, wherein X_3 is phenyl.

22. A compound according to claim 18, wherein X_3 is furyl, thienyl, benzothienyl or benzofuranyl optionally substituted with one or more substituents selected from halogen, C_{1-6}-alkyl or perhalomethyl.

23. A compound according to claim 22, wherein X_3 is furyl optionally substituted with one or more substituents selected from halogen, C_{1-6}-alkyl or trifluoromethyl.

24. A compound according to claim 22, wherein X_3 is thienyl optionally substituted with one or more substituents selected from halogen, C_{1-6}-alkyl or trifluoromethyl.

25. A compound according to claim 22, wherein X_3 is benzothienyl optionally substituted with one or more substituents selected from halogen, C_{1-6}-alkyl or trifluoromethyl.

26. A compound according to claim 22, wherein X_3 is benzofuranyl optionally substituted with one or more substituents selected from halogen, C_{1-6}-alkyl or trifluoromethyl.

27. A compound according to claim 1, wherein Ar is phenylene which is optionally substituted with one or more substituents selected from

- halogen, hydroxy or cyano; or
- C_{1-6}-alkyl, C_{3-6}-cycloalkyl, C_{2-6}-alkenyl, C_{2-6}-alkynyl, aryl, heteroaryl, aralkyl, heteroaralkyl, C_{1-6}-alkoxy, C_{3-6}-cycloalkoxy, aryloxy, aralkoxy, heteroaralkoxy, C_{1-6}-alkylthio, arylthio or C_{3-6}-cycloalkylthio each of which is optionally substituted with one or more halogens.

28. A compound according to claim 27, wherein Ar is phenylene which is optionally substituted with one or more substituents selected from

- halogen; or
- C_{1-6}-alkyl, C_{1-6}-alkoxy, aryloxy or aralkoxy each of which is optionally substituted with one or more halogens.

29. A compound according to claim 28, wherein Ar is phenylene which is optionally substituted with methyl.

30. A compound according to claim 29, wherein Ar is phenylene.

31. A compound according to claim 1, wherein Y_1 is S.

32. A compound according to claim 1, wherein Y_2 is O.

33. A compound according to claim 1, wherein n is 1.

34. A compound according to claim 1, wherein R_1 is hydrogen or a substituent selected from C_{1-6}-alkyl, aralkyl, C_{1-6}-alkoxy, aryloxy, aralkoxy each of which is optionally substituted with one or more halogens.

35. A compound according to claim 34, wherein R_1 is hydrogen or a substituent selected from C_{1-6}-alkyl or C_{1-6}-alkoxy each of which is optionally substituted with one or more halogens.

36. A compound according to claim 35, wherein R_1 is hydrogen.

37. A compound according to claim 1, wherein R_2 is hydrogen.

38. A compound according to claim 1, wherein R_2 is methyl or ethyl.

39. A compound according to claim 1, which is selected from the following:
(E/Z) {4-[3-Biphenyl-4-yl-3-(4-bromo-phenyl)-allylsulfanyl]-phenoxy}-acetic acid, and
(E/Z) {4-[3-(4-Bromo-phenyl)-3-(3'-trifluoromethyl-biphenyl-4-yl)-allylsulfanyl]-2-methyl-phenoxy}-acetic acid; or
a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, tautomeric form, stereoisomer, mixture of stereoisomers, racemic mixture, or polymorphs thereof.

40. A compound according to claim 1, which is selected from the following:
{4-[3-(4-Bromo-phenyl)-3-[1,1';4',1"]terphenyl-4"-yl-allylsulfanyl]-2-methyl-phenoxy}-acetic acid;
(E/Z)-[2-Methyl-4-[3-[5-(5-methylthiophen-2-yl)benzo[b]furan-2-yl]-3-(thiophen-2-yl)allyl-sulfanyl]phenoxy]acetic acid;
(E/Z)-[4-[3-(Biphenyl-4-yl)-3-(furan-2-yl)allylsulfanyl]-2-methylphenoxy]acetic acid;
(E/Z)-[4-[3-(Benzo[b]thiophen-3-yl)-3-(biphenyl-4-yl)allylsulfanyl]-2-methylphenoxy]acetic acid;
[4-[(3-Benzo[b]thiophen-2-yl)-3-(biphenyl-4-yl)-allylsulfanyl]-2-methyl-phenoxy]-acetic acid; and
(E/Z)-[4-[3-(4-Biphenylyl)-3-(5-methylthiophen-2-yl)allylsulfanyl]-2-methylphenoxy]acetic acid; or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, tautomeric form, stereoisomer, mixture of stereoisomers, racemic mixture, or polymorphs thereof.

41. A compound according to claim 1, which is selected from the following:

(E) {4-[3-Biphenyl-4-yl-3-(2-fluoro-phenyl)-allylsulfanyl]-phenoxy}-acetic acid;

(Z) {4-[3-Biphenyl-4-yl-3-(2-fluoro-phenyl)-allylsulfanyl]-phenoxy}-acetic acid;

(E) {4-[3-Biphenyl-4-yl-3-(2-chloro-phenyl)-allylsulfanyl]-phenoxy}-acetic acid;

(Z) {4-[3-Biphenyl-4-yl-3-(2-chloro-phenyl)-allylsulfanyl]-phenoxy}-acetic acid;

(E) {4-[3-Biphenyl-4-yl-3-(2-bromo-phenyl)-allylsulfanyl]-phenoxy}-acetic acid;

(Z) {4-[3-Biphenyl-4-yl-3-(2-bromo-phenyl)-allylsulfanyl]-phenoxy}-acetic acid;

(E) {4-[3-Biphenyl-4-yl-3-(2-iodo-phenyl)-allylsulfanyl]-phenoxy}-acetic acid;

(Z) {4-[3-Biphenyl-4-yl-3-(2-iodo-phenyl)-allylsulfanyl]-phenoxy}-acetic acid;

(E) {4-[3-Biphenyl-4-yl-3-(2-methoxy-phenyl)-allylsulfanyl]-phenoxy}-acetic acid;

(Z) {4-[3-Biphenyl-4-yl-3-(2-methoxy-phenyl)-allylsulfanyl]-phenoxy}-acetic acid;

(E) {4-[3-Biphenyl-4-yl-3-(2-trifluoromethoxy-phenyl)-allylsulfanyl]-phenoxy}-acetic acid;

(Z) {4-[3-Biphenyl-4-yl-3-(2-trifluoromethoxy-phenyl)-allylsulfanyl]-phenoxy}-acetic acid;

(E) {4-[3-Biphenyl-4-yl-3-(2-methyl-phenyl)-allylsulfanyl]-phenoxy}-acetic acid;

(Z) {4-[3-Biphenyl-4-yl-3-(2-methyl-phenyl)-allylsulfanyl]-phenoxy}-acetic acid;

(E) {4-[3-Biphenyl-4-yl-3-(2-trifluoromethyl-phenyl)-allylsulfanyl]-phenoxy}-acetic acid;

(Z) {4-[3-Biphenyl-4-yl-3-(2-trifluoromethyl-phenyl)-allylsulfanyl]-phenoxy}-acetic acid;

(E) {4-[3-Biphenyl-4-yl-3-(3-fluoro-phenyl)-allylsulfanyl]-phenoxy}-acetic acid;

(Z) {4-[3-Biphenyl-4-yl-3-(3-fluoro-phenyl)-allylsulfanyl]-phenoxy}-acetic acid;

(E) {4-[3-Biphenyl-4-yl-3-(3-chloro-phenyl)-allylsulfanyl]-phenoxy}-acetic acid;

(Z) {4-[3-Biphenyl-4-yl-3-(3-chloro-phenyl)-allylsulfanyl]-phenoxy}-acetic acid;

(E) {4-[3-Biphenyl-4-yl-3-(3-bromo-phenyl)-allylsulfanyl]-phenoxy}-acetic acid;

(Z) {4-[3-Biphenyl-4-yl-3-(3-bromo-phenyl)-allylsulfanyl]-phenoxy}-acetic acid;

(E) {4-[3-Biphenyl-4-yl-3-(3-iodo-phenyl)-allylsulfanyl]-phenoxy}-acetic acid;

(Z) {4-[3-Biphenyl-4-yl-3-(3-iodo-phenyl)-allylsulfanyl]-phenoxy}-acetic acid;

(E) {4-[3-Biphenyl-4-yl-3-(3-methoxy-phenyl)-allylsulfanyl]-phenoxy}-acetic acid;

(Z) {4-[3-Biphenyl-4-yl-3-(3-methoxy-phenyl)-allylsulfanyl]-phenoxy}-acetic acid;

(E) {4-[3-Biphenyl-4-yl-3-(3-trifluoromethoxy-phenyl)-allylsulfanyl]-phenoxy}-acetic acid;

(Z) {4-[3-Biphenyl-4-yl-3-(3-trifluoromethoxy-phenyl)-allylsulfanyl]-phenoxy}-acetic acid;

(E) {4-[3-Biphenyl-4-yl-3-(3-methyl-phenyl)-allylsulfanyl]-phenoxy}-acetic acid;

(Z) {4-[3-Biphenyl-4-yl-3-(3-methyl-phenyl)-allylsulfanyl]-phenoxy}-acetic acid;

(E) {4-[3-Biphenyl-4-yl-3-(3-trifluoromethyl-phenyl)-allylsulfanyl]-phenoxy}-acetic acid;

(Z) {4-[3-Biphenyl-4-yl-3-(3-trifluoromethyl-phenyl)-allylsulfanyl]-phenoxy}-acetic acid;

(E) {4-[3-Biphenyl-4-yl-3-(4-fluoro-phenyl)-allylsulfanyl]-phenoxy}-acetic acid;

(Z) {4-[3-Biphenyl-4-yl-3-(4-fluoro-phenyl)-allylsulfanyl]-phenoxy}-acetic acid;

(E) {4-[3-Biphenyl-4-yl-3-(4-chloro-phenyl)-allylsulfanyl]-phenoxy}-acetic acid;

(Z) {4-[3-Biphenyl-4-yl-3-(4-chloro-phenyl)-allylsulfanyl]-phenoxy}-acetic acid;

(E/Z) {4-[3-Biphenyl-4-yl-3-(4-bromo-phenyl)-allylsulfanyl]-phenoxy}-acetic acid;

(E) {4-[3-Biphenyl-4-yl-3-(4-bromo-phenyl)-allylsulfanyl]-phenoxy}-acetic acid;

(Z) {4-[3-Biphenyl-4-yl-3-(4-bromo-phenyl)-allylsulfanyl]-phenoxy}-acetic acid;

(E) {4-[3-Biphenyl-4-yl-3-(4-iodo-phenyl)-allylsulfanyl]-phenoxy}-acetic acid;

(Z) {4-[3-Biphenyl-4-yl-3-(4-iodo-phenyl)-allylsulfanyl]-phenoxy}-acetic acid;

(E) {4-[3-Biphenyl-4-yl-3-(4-methoxy-phenyl)-allylsulfanyl]-phenoxy}-acetic acid;

(Z) {4-[3-Biphenyl-4-yl-3-(4-methoxy-phenyl)-allylsulfanyl]-phenoxy}-acetic acid;

(E) {4-[3-Biphenyl-4-yl-3-(4-trifluoromethoxy-phenyl)-allylsulfanyl]-phenoxy}-acetic acid;

(Z) {4-[3-Biphenyl-4-yl-3-(4-trifluoromethoxy-phenyl)-allylsulfanyl]-phenoxy}-acetic acid;

(E) {4-[3-Biphenyl-4-yl-3-(4-methyl-phenyl)-allylsulfanyl]-phenoxy}-acetic acid;

(Z) {4-[3-Biphenyl-4-yl-3-(4-methyl-phenyl)-allylsulfanyl]-phenoxy}-acetic acid;

(E) {4-[3-Biphenyl-4-yl-3-(4-trifluoromethyl-phenyl)-allylsulfanyl]-phenoxy}-acetic acid;

(Z) {4-[3-Biphenyl-4-yl-3-(4-trifluoromethyl-phenyl)-allylsulfanyl]-phenoxy}-acetic acid;

(E) {4-[3-(4-Fluoro-phenyl)-3-(2'-trifluoromethyl-biphenyl-4-yl)-allylsulfanyl]-2-methyl-phenoxy}-acetic acid;

(Z) {4-[3-(4-Fluoro-phenyl)-3-(2'-trifluoromethyl-biphenyl-4-yl)-allylsulfanyl]-2-methyl-phenoxy}-acetic acid;

(E/Z) {4-[3-(4-Fluoro-phenyl)-3-(3'-trifluoromethyl-biphenyl-4-yl)-allylsulfanyl]-2-methyl-phenoxy}-acetic acid;

(E) {4-[3-(4-Fluoro-phenyl)-3-(3'-trifluoromethyl-biphenyl-4-yl)-allylsulfanyl]-2-methyl-phenoxy}-acetic acid;

(Z) {4-[3-(4-Fluoro-phenyl)-3-(3'-trifluoromethyl-biphenyl-4-yl)-allylsulfanyl]-2-methyl-phenoxy}-acetic acid;

(E) {4-[3-(4-Fluoro-phenyl)-3-(4'-trifluoromethyl-biphenyl-4-yl)-allylsulfanyl]-2-methyl-phenoxy}-acetic acid;

(Z) {4-[3-(4-Fluoro-phenyl)-3-(4'-trifluoromethyl-biphenyl-4-yl)-allylsulfanyl]-2-methyl-phenoxy}-acetic acid;

(E) {4-[3-(4-Fluoro-phenyl)-3-(3'-chloro-biphenyl-4-yl)-allylsulfanyl]-2-methyl-phenoxy}-acetic acid;

(Z) {4-[3-(4-Fluoro-phenyl)-3-(3'-chloro-biphenyl-4-yl)-allylsulfanyl]-2-methyl-phenoxy}-acetic acid;

(E) {4-[3-(4-Fluoro-phenyl)-3-(4'-chloro-biphenyl-4-yl)-allylsulfanyl]-2-methyl-phenoxy}-acetic acid;

(Z) {4-[3-(4-Fluoro-phenyl)-3-(4'-chloro-biphenyl-4-yl)-allylsulfanyl]-2-methyl-phenoxy}-acetic acid;

(E) {4-[3-(4-Fluoro-phenyl)-3-(3'-methoxy-biphenyl-4-yl)-allylsulfanyl]-2-methyl-phenoxy}-acetic acid;

(Z) {4-[3-(4-Fluoro-phenyl)-3-(3'-methoxy-biphenyl-4-yl)-allylsulfanyl]-2-methyl-phenoxy}-acetic acid;

(E) {4-[3-(4-Fluoro-phenyl)-3-(4'-methoxy-biphenyl-4-yl)-allylsulfanyl]-2-methyl-phenoxy}-acetic acid;

(Z) {4-[3-(4-Fluoro-phenyl)-3-(4'-methoxy-biphenyl-4-yl)-allylsulfanyl]-2-methyl-phenoxy}-acetic acid;

(E) {4-[3-(4-Chloro-phenyl)-3-(2'-trifluoromethyl-biphenyl-4-yl)-allylsulfanyl]-2-methyl-phenoxy}-acetic acid;

(Z) {4-[3-(4-Chloro-phenyl)-3-(2'-trifluoromethyl-biphenyl-4-yl)-allylsulfanyl]-2-methyl-phenoxy}-acetic acid;

(E/Z) {4-[3-(4-Chloro-phenyl)-3-(3'-trifluoromethyl-biphenyl-4-yl)-allylsulfanyl]-2-methyl-phenoxy}-acetic acid;

(E) {4-[3-(4-Chloro-phenyl)-3-(3'-trifluoromethyl-biphenyl-4-yl)-allylsulfanyl]-2-methyl-phenoxy}-acetic acid;

(Z) {4-[3-(4-Chloro-phenyl)-3-(3'-trifluoromethyl-biphenyl-4-yl)-allylsulfanyl]-2-methyl-phenoxy}-acetic acid;

(E) {4-[3-(4-Chloro-phenyl)-3-(4'-trifluoromethyl-biphenyl-4-yl)-allylsulfanyl]-2-methyl-phenoxy}-acetic acid;

(Z) {4-[3-(4-Chloro-phenyl)-3-(4'-trifluoromethyl-biphenyl-4-yl)-allylsulfanyl]-2-methyl-phenoxy}-acetic acid;

(E) {4-[3-(4-Chloro-phenyl)-3-(3'-chloro-biphenyl-4-yl)-allylsulfanyl]-2-methyl-phenoxy}-acetic acid;

(Z) {4-[3-(4-Chloro-phenyl)-3-(3'-chloro-biphenyl-4-yl)-allylsulfanyl]-2-methyl-phenoxy}-acetic acid;

(E) {4-[3-(4-Chloro-phenyl)-3-(4'-chloro-biphenyl-4-yl)-allylsulfanyl]-2-methyl-phenoxy}-acetic acid;

(Z) {4-[3-(4-Chloro-phenyl)-3-(4'-chloro-biphenyl-4-yl)-allylsulfanyl]-2-methyl-phenoxy}-acetic acid;

(E) {4-[3-(4-Chloro-phenyl)-3-(3'-methoxy-biphenyl-4-yl)-allylsulfanyl]-2-methyl-phenoxy}-acetic acid;

(Z) {4-[3-(4-Chloro-phenyl)-3-(3'-methoxy-biphenyl-4-yl)-allylsulfanyl]-2-methyl-phenoxy}-acetic acid;

(E) {4-[3-(4-Chloro-phenyl)-3-(4'-methoxy-biphenyl-4-yl)-allylsulfanyl]-2-methyl-phenoxy}-acetic acid;

(Z) {4-[3-(4-Chloro-phenyl)-3-(4'-methoxy-biphenyl-4-yl)-allylsulfanyl]-2-methyl-phenoxy}-acetic acid;

(E) {4-[3-(4-Bromo-phenyl)-3-(2'-trifluoromethyl-biphenyl-4-yl)-allylsulfanyl]-2-methyl-phenoxy}-acetic acid;

(Z) {4-[3-(4-Bromo-phenyl)-3-(2'-trifluoromethyl-biphenyl-4-yl)-allylsulfanyl]-2-methyl-phenoxy}-acetic acid;

(E/Z) {4-[3-(4-Bromo-phenyl)-3-(3'-trifluoromethyl-biphenyl-4-yl)-allylsulfanyl]-2-methyl-phenoxy}-acetic acid;

(E) {4-[3-(4-Bromo-phenyl)-3-(3'-trifluoromethyl-biphenyl-4-yl)-allylsulfanyl]-2-methyl-phenoxy}-acetic acid;

(Z) {4-[3-(4-Bromo-phenyl)-3-(3'-trifluoromethyl-biphenyl-4-yl)-allylsulfanyl]-2-methyl-phenoxy}-acetic acid;

(E) {4-[3-(4-Bromo-phenyl)-3-(4'-trifluoromethyl-biphenyl-4-yl)-allylsulfanyl]-2-methyl-phenoxy}-acetic acid;

(Z) {4-[3-(4-Bromo-phenyl)-3-(4'-trifluoromethyl-biphenyl-4-yl)-allylsulfanyl]-2-methyl-phenoxy}-acetic acid;

(E) {4-[3-(4-Bromo-phenyl)-3-(3'-chloro-biphenyl-4-yl)-allylsulfanyl]-2-methyl-phenoxy}-acetic acid;

(Z) {4-[3-(4-Bromo-phenyl)-3-(3'-chloro-biphenyl-4-yl)-allylsulfanyl]-2-methyl-phenoxy}-acetic acid;

(E) {4-[3-(4-Bromo-phenyl)-3-(4'-chloro-biphenyl-4-yl)-allylsulfanyl]-2-methyl-phenoxy}-acetic acid;

(Z) {4-[3-(4-Bromo-phenyl)-3-(4'-chloro-biphenyl-4-yl)-allylsulfanyl]-2-methyl-phenoxy}-acetic acid;

(E) {4-[3-(4-Bromo-phenyl)-3-(3'-methoxy-biphenyl-4-yl)-allylsulfanyl]-2-methyl-phenoxy}-acetic acid;

(Z) {4-[3-(4-Bromo-phenyl)-3-(3'-methoxy-biphenyl-4-yl)-allylsulfanyl]-2-methyl-phenoxy}-acetic acid;

(E) {4-[3-(4-Bromo-phenyl)-3-(4'-methoxy-biphenyl-4-yl)-allylsulfanyl]-2-methyl-phenoxy}-acetic acid; and

(Z) {4-[3-(4-Bromo-phenyl)-3-(4'-methoxy-biphenyl-4-yl)-allylsulfanyl]-2-methyl-phenoxy}-acetic acid; or

a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, tautomeric form, stereoisomer, mixture of stereoisomers, racemic mixture, or polymorphs thereof.

42. A compound according to claim 1, which is a PPARδ agonist.

43. A compound according to claim 42, which is a selective PPARδ agonist.

44. A pharmaceutical composition comprising, as an active ingredient, at least one compound according to claim 1, together with one or more pharmaceutically acceptable carriers or excipients.

45. A pharmaceutical composition according to claim 44 in unit dosage form, comprising from about 0.05 mg to about 1000 mg, preferably from about 0.1 to about 500 mg of and especially preferred from about 0.5 mg to about 200 mg per day of compound according to claim 1.

46. A pharmaceutical composition for the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR), the composition comprising a compound according to claim 1 together with one or more pharmaceutically acceptable carriers or excipients.

47. A pharmaceutical composition for the treatment and/or prevention of type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance or obesity comprising a compound according to claim 1 together with one or more pharmaceutically acceptable carriers or excipients.

48. A pharmaceutical composition according to any one of the claim 44 for oral, nasal, transdermal, pulmonal, or parenteral administration.

49. A method for the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR), the method

comprising administering to a subject in need thereof an effective amount of a compound according to claim 1 or a pharmaceutical composition comprising the same.

50. A method for the treatment and/or prevention of type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance or obesity, the method comprising administering to a subject in need thereof an effective amount of a compound according to claim 1 or of a pharmaceutical composition comprising the same.

51. The method according to claim 49 wherein the effective amount of the compound according to claim 1 is in the range of from about 0.05 mg to about 1000 mg, preferably from about 0.1 to about 500 mg of and especially preferred from about 0.5 mg to about 200 mg per day.

52. The method according to claim 50 wherein the effective amount of the compound according to claim 1 is in the range of from about 0.05 mg to about 1000 mg, preferably from about 0.1 to about 500 mg of and especially preferred from about 0.5 mg to about 200 mg per day.